Qiagen N.v. · NYSE:QGEN

Qiagen — Investor Day (November 2016)

13 slides from Qiagen's investor day presentation, Nov 15, 2016

  1. Slide 1: Commercial Operations: Engaging customers with our Sample to Insight portfolio

    Commercial Operations: Engaging customers with our Sample to Insight portfolio Manuel O. Méndez Senior Vice President, Head of Global Commercial Operations November 15, 2016 Sample to Insight 2016 Analyst & Investor Day 1

  2. Slide 2: Disclaimer

    Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended

  3. Slide 3: Sample to Insight

    Sample to Insight 2016 Analyst & Investor Day 3

  4. Slide 4: QIAGEN benefitting from increasing prevalence and pace of molecular testing

    Commercial Operations Waltham, Manchester, Massachusetts England Manuel O. Méndez Senior Vice President, Hilden, Shenzen, Global Commercial Operations China Germany Joined QIAGEN in 2014 2015 total sales: ~$1.3 billion Germantown, Wroclaw, Commercial Operations employees: ~1,800 Maryland Poland Oppo

  5. Slide 5: QIAGEN implications

    QIAGEN implications Clinical trends drive growth  Strengthen role as top 3 global competitor  Leverage access to ~80% of $5-6 bn MDx market Cost of ownership  Target growth in areas with differentiated profile:  Oncology Multiple decision makers  Immune Monitoring MDx  Infectious Diseases Frag

  6. Slide 6: Strategy: Deliver solid sales growth efficiently as leader in enabling insights

    Drive commercial teams with efficiency and effectiveness Experienced leaders using data-driven tools Invest in geographic expansion Capitalizing on established and emerging markets Optimize customer engagement Omni-channel approach using multiple channels Create value with our Sample to Insight port

  7. Slide 7: Significant executive leadership changes implemented while growing sales

    NEW TO QIAGEN Manuel O. Méndez Mohammad El Khoury President (Interim) President Commercial Operations Commercial Operations North America Europe / Middle East / Africa Formerly bioMerieux, Abbott, Thermo Formerly GE, bioMerieux NEW TO QIAGEN NEW ROLE Enrique Razzeto Ian Martin Vice President Preside

  8. Slide 8: Results and accountability driven-culture

    Results and accountability driven-culture QIAGEN sales trends (CER % change)  New “go-to-market” strategy 9% 7% 5% 6% 5% 5% 4% 4%  Leading and lagging indicators 3% 3% 4% 2% 2% 3% 2%  Pipeline management Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3  Demand generation 2013 2013 2013 2013 2014 201

  9. Slide 9: Emerging markets

    Emerging markets  Expanding commercial partner network  Case study: >20% CER in 2016 Direct QIAGEN presence  Dubai, Thailand  Case study: South Africa >50% CER in 2016 Geographic expansion Established markets  North America investments in QuantiFERON  Case study: >28% CER growth in 2016  Flex

  10. Slide 10: Omni-channel customer engagement creates value with digital accessibility

    Academia Pharma Applied Testing Molecular Diagnostics Scientific breakthroughs Better and safer drugs Secure and protect Better healthcare Generalists and Specialists Direct mail Mobile content Marketing automation Websites Inside Sales eCommerce Customer Care Field Service Support Case studies Sale

  11. Slide 11: Leverage Sample to Insight portfolio for customer types and preferred channels

    Academia Pharma Applied Testing Molecular Diagnostics Scientific breakthroughs Better and safer drugs Secure and protect Better healthcare Case study: New York Memorial Sloan Kettering Pfizer Pharmaceuticals New York University (NYU) NYC Chief Medical Examiner Leverage Sample to Insight portfolio fo

  12. Slide 12: Sample to Insight workflows creating value for many customers

    Case study: Leveraging benefits of NGS Sample to Insight workflows Platform agnostic Nucleic acid Target Library Data collection & Interpretation enrichment preparation analysis extraction GeneReader NGS System Automation QIAcube QIAgility QIAcube GeneRead Gene- QCI- QCI- QIAcube Reader Analyze Inte

  13. Slide 13: Experienced commercial team using data-driven tools

    Experienced commercial team using data-driven tools Targeted geographic investments to accelerate growth Optimizing customer engagement in multiple channels Agile and focused teams with improved sales efficiency Sample to Insight 2016 Analyst & Investor Day 13

Qiagen — Investor Day (November 2016) on 6ix